본문으로 건너뛰기
← 뒤로

Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma.

1/5 보강
BMC cancer 2026 Vol.26(1)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: HCC, indicating its potential value as a prognostic biomarker
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
More trials with large numbers of patients are imperative to validate its application as a beneficial biomarker for ICIs. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15652-9.

Ni Z, Gu J, Qiu Q, Li Y, Tian Z, Liu G, Mei J, Yang J, Sun L

📝 환자 설명용 한 줄

[UNLABELLED] Immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape for advanced cancers; however, a substantial proportion of patients fail to benefit from ICI therapy, and reliabl

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ni Z, Gu J, et al. (2026). Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma.. BMC cancer, 26(1). https://doi.org/10.1186/s12885-026-15652-9
MLA Ni Z, et al.. "Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma.." BMC cancer, vol. 26, no. 1, 2026.
PMID 41629879

Abstract

[UNLABELLED] Immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape for advanced cancers; however, a substantial proportion of patients fail to benefit from ICI therapy, and reliable predictive biomarkers remain limited. This study aimed to investigate the immunological relevance of helicase-like transcription factor (HLTF) and its potential therapeutic implications in hepatocellular carcinoma (HCC). HLTF expression was elevated across multiple cancer types, with particularly high levels observed in HCC. Increased HLTF expression was significantly associated with advanced tumor stage, higher histological grade, TP53 mutations, and lymph node metastasis. Moreover, high HLTF expression correlated with poorer overall survival, disease-specific survival, and progression-free interval in patients with HCC, indicating its potential value as a prognostic biomarker. Consistent with data from the Human Protein Atlas, HLTF protein expression was 74.51% higher in HCC tissues than in adjacent non-tumor tissues, and a similar pattern was observed at the transcriptional level. Immune infiltration analysis revealed a negative association between HLTF expression and CD8⁺ T cell infiltration, despite notable HLTF enrichment within CD8⁺ T cells themselves. Clear differences in pDC/CD8 T cells were observed between HLTF-high and HLTF-low subgroups, further supporting an inverse relationship between HLTF and CD8⁺ T cells in HCC TMA cohorts. In addition, we observed that tumor tissues from nonresponders displayed greater levels of HLTF compared to those from responders in our cohort. Taken together, our study points out that HLTF acts as a critical marker that dwindles the effectiveness of ICIs in HCC sufferers. More trials with large numbers of patients are imperative to validate its application as a beneficial biomarker for ICIs.

[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15652-9.

같은 제1저자의 인용 많은 논문 (5)